Loading...
01/11 03:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Revenue for Q3 2025 $7.5 million, a decrease from $9.2 million in the prior year third quarter. The decline was due to lower system revenue, partially offset by growth in recurring revenue.
System Revenue for Q3 2025 $1.9 million, compared to $4.4 million in the prior year third quarter. The decrease reflects partial revenue recognition on 1 Genesis system and ancillary devices.
Recurring Revenue for Q3 2025 $5.6 million, compared to $4.8 million in the prior year third quarter. The increase reflects a full quarter's contribution of Map-iT catheters and initial sales of new robotically navigated devices.
Gross Margin for Q3 2025 55% of revenue. Recurring revenue gross margin was 67%, and system gross margin was 19%. Gross margins remain impacted by fixed overhead allocated over low production levels.
Operating Expenses for Q3 2025 $10.7 million, including $4.1 million in noncash charges. Adjusted operating expenses were $6.6 million, a decrease from $7.2 million in the prior year third quarter due to lower general and administrative expenses.
Operating Loss for Q3 2025 $6.6 million, compared to $6.3 million in the prior year third quarter. Adjusted operating loss was $2.5 million, compared to $3.1 million in the prior year third quarter.
Net Loss for Q3 2025 $6.5 million, compared to $6.2 million in the prior year third quarter. Adjusted net loss was $2.4 million, compared to $3 million in the prior year third quarter.
Negative Free Cash Flow for Q3 2025 $4.2 million, consistent with the previous year.
Cash and Cash Equivalents as of September 30, 2025 $10.5 million, with no debt. Including $4 million from the upcoming second closing of registered direct financing, cash would have been $14.5 million.
GenesisX System: Received FDA approval, marking a significant milestone for Stereotaxis. Limited launch initiated, with expectations for full launch after refining supply chain and manufacturing processes.
MAGiC Sweep Catheter: First catheter launch in the U.S., generating $300,000 in revenue within the first two months. Allows for better diagnosis of arrhythmias and enables new clinical applications.
Synchrony and SynX Digital Cath Lab System: Obtained CE Mark in Europe and submitted for FDA approval. Expected to generate a couple of million dollars in revenue in the first year of launch.
European Market Expansion: Two Genesis robots ordered by European hospitals, reflecting strong interest and a more complete product ecosystem in the region.
MAGiC Sweep Catheter in Europe: Plans to gain approval and launch in Europe, following its successful U.S. launch.
Recurring Revenue Growth: Recurring revenue grew to $5.6 million in Q3 2025, driven by new catheter sales and service contracts.
Gross Margin: Gross margin for Q3 2025 was 55%, with recurring revenue gross margin at 67%.
Razor-Razorblade Business Model: Focus on scaling robotic system sales and building a high-margin recurring revenue business with novel catheters.
PFA Collaboration with CardioFocus: Entered into a collaboration to integrate CardioFocus' PFA system with the MAGiC catheter, aiming for first-in-human testing and potential European approval by the end of 2026.
Regulatory Approval Delays: The company is awaiting FDA approval for the MAGiC catheter in the U.S., which could delay the full launch of GenesisX and impact revenue growth.
Supply Chain and Manufacturing Challenges: The company is refining its supply chain and manufacturing processes for GenesisX, which could pose risks to timely production and delivery.
Limited Adoption of New Products: MAGiC Sweep catheter has only been adopted by about 25% of robotic accounts in the U.S., indicating potential challenges in scaling adoption.
Financial Losses and Cash Flow: The company reported an operating loss of $6.6 million and negative free cash flow of $4.2 million for the quarter, which could impact its ability to fund future operations and innovations.
Market Competition: The electrophysiology field is experiencing significant market growth and share shifts among large med-tech players, posing competitive pressures on Stereotaxis.
Economic Dependency on Recurring Revenue: The company’s recurring revenue is heavily reliant on the adoption of its proprietary catheters, which could be a risk if adoption rates do not meet expectations.
Technological and Product Development Risks: The company is investing in multiple late-stage and early-stage innovation projects, which may not all succeed or generate expected returns.
Revenue Expectations: Revenue for the fourth quarter of 2025 is expected to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million. This will result in over 20% annual revenue growth for the full year 2025. Quarterly revenue is expected to surpass an average of $10 million per quarter in 2026.
Product Launches and Market Trends: The GenesisX system has received FDA approval, and a limited launch is underway. Full launch is expected after enhancements to compatibility, supply chain, and commercial processes. GenesisX orders are anticipated to outpace Genesis orders post-launch. The MAGiC Sweep catheter has shown strong initial adoption in the U.S., with plans for European approval and launch. The MAGiC catheter is expected to gain U.S. FDA approval soon, with potential for PFA use in Europe by the end of 2026. Synchrony and SynX digital solutions are expected to contribute a couple of million dollars in revenue in their first year of launch, with potential for a growing SaaS revenue stream.
Growth Expectations: Sustained growth in both systems and recurring revenue is expected through 2026, driven by the GenesisX launch and increased adoption of MAGiC, MAGiC Sweep, and Map-iT catheters. The company anticipates achieving profitability with improved margins and earnings accretion.
Capital Expenditures and Financial Position: The company expects to enter 2026 with a healthy balance sheet, enabling the advancement and launch of new technologies while maintaining a focus on growth and profitability.
The selected topic was not discussed during the call.
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
Despite a 39% increase in Q4 revenue, operating losses have widened, and there are significant supply chain challenges. The absence of a share repurchase program and conservative guidance further dampen sentiment. While there are promising product developments, regulatory and market uncertainties, especially in China, pose risks. The Q&A session highlighted management's inability to provide clear timelines for key product approvals, adding to investor concerns. Overall, the negative financial indicators and uncertainties outweigh the positive revenue growth.
The earnings call reveals mixed signals: strong revenue growth in Q4 2024 and positive free cash flow, but financial losses and dependency on Johnson & Johnson pose risks. The Q&A shows uncertainty in revenue guidance and regulatory approvals, with vague responses from management. The lack of shareholder return plans and the company's financial strain further balance the positive aspects, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
